HERON THERAPEUTICS, INC. /DE/ (HRTX) Quick Ratio
- Quick ratio · latest quarter: Value 1.44×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.44× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $132.24M ÷ $92.14M ≈ 1.44× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 132.24M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 92.14M USD | Liabilities, Current |
| Cash and equivalents | 20.72M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 21.94M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 89.57M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 90.58M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $132.24M | $92.14M | $20.72M | $21.94M | $89.57M | $90.58M | 1.44× |
| 2026-03-31 | $128.48M | $90.52M | $26.12M | $18.67M | $83.69M | $92.54M | 1.42× |
| 2025-12-31 | $136.22M | $96.10M | $28.65M | $17.98M | $89.59M | $92.75M | 1.42× |
| 2025-09-30 | $136.53M | $89.71M | $43.07M | $12.42M | $81.05M | $70.03M | 1.52× |
| 2025-06-30 | $120.56M | $258.60M | $16.52M | $24.12M | $79.93M | $72.97M | 0.47× |
| 2025-03-31 | $129.41M | $88.56M | $19.27M | $31.41M | $78.74M | $56.93M | 1.46× |
| 2024-12-31 | $138.16M | $91.46M | $25.80M | $33.48M | $78.88M | $53.16M | 1.51× |
| 2024-09-30 | $137.93M | $85.54M | $25.74M | $45.15M | $67.04M | $45.95M | 1.61× |
| 2024-06-30 | $141.06M | $80.32M | $18.39M | $48.96M | $73.71M | $42.86M | 1.76× |
| 2024-03-31 | $136.85M | $75.38M | $20.45M | $51.07M | $65.32M | $42.47M | 1.82× |
| 2023-12-31 | $140.55M | $79.69M | $28.68M | $51.73M | $60.14M | $42.11M | 1.76× |
| 2023-09-30 | $141.21M | $79.75M | $34.86M | $42.55M | $63.80M | $42.01M | 1.77× |
| 2023-06-30 | $109.94M | $86.72M | $13.46M | $19.78M | $76.69M | $44.62M | 1.27× |
| 2023-03-31 | $111.47M | $77.90M | $27.09M | $32.93M | $51.45M | $52.06M | 1.43× |
| 2022-12-31 | $136.90M | $82.36M | $15.36M | $69.49M | $52.05M | $54.57M | 1.66× |
| 2022-09-30 | $163.93M | $93.88M | $50.44M | $71.31M | $42.19M | $52.24M | 1.75× |
| 2022-06-30 | $123.84M | $109.50M | $48.61M | $34.93M | $40.30M | $61.32M | 1.13× |
| 2022-03-31 | $153.01M | $93.00M | $56.91M | $55.00M | $41.10M | $56.47M | 1.65× |
| 2021-12-31 | $193.08M | $71.06M | $90.54M | $67.04M | $35.50M | $48.38M | 2.72× |
| 2021-09-30 | $245.91M | $72.30M | $159.57M | $43.25M | $43.09M | $41.50M | 3.40× |
| 2021-06-30 | $300.29M | $82.14M | $191.17M | $66.50M | $42.62M | $42.80M | 3.66× |
| 2021-03-31 | $204.99M | $100.92M | $59.74M | $106.73M | $38.52M | $42.63M | 2.03× |
| 2020-12-31 | $250.34M | $102.50M | $105.14M | $103.35M | $41.85M | $41.91M | 2.44× |
| 2020-09-30 | $291.80M | $97.58M | $95.14M | $163.00M | $33.65M | $42.75M | 2.99× |
| 2020-06-30 | $338.34M | $92.65M | $80.73M | $220.11M | $37.50M | $41.44M | 3.65× |
| 2020-03-31 | $391.16M | $96.77M | $103.28M | $253.06M | $34.81M | $34.85M | 4.04× |
| 2019-12-31 | $430.85M | $96.70M | $71.90M | $319.07M | $39.88M | $24.97M | 4.46× |
| 2019-09-30 | $323.23M | $96.74M | $60.11M | $196.17M | $66.95M | $24.17M | 3.34× |
| 2019-06-30 | $342.83M | $95.06M | $53.04M | $222.97M | $66.82M | $29.27M | 3.61× |
| 2019-03-31 | $363.25M | $92.26M | $23.46M | $265.78M | $74.01M | $31.42M | 3.94× |
| 2018-12-31 | $397.02M | $92.02M | $31.84M | $300.54M | $64.65M | $39.03M | 4.31× |
| 2018-09-30 | $418.43M | $64.09M | $53.93M | $310.87M | $53.63M | $31.41M | 6.53× |
| 2018-06-30 | $468.85M | $78.67M | $258.93M | $164.03M | $45.89M | $27.20M | 5.96× |
| 2018-03-31 | $151.65M | $91.18M | $46.58M | $67.36M | $37.71M | $19.42M | 1.66× |
| 2017-12-31 | $214.25M | $103.17M | $144.58M | $27.80M | $41.87M | $10.11M | 2.08× |
| 2017-09-30 | $102.87M | $53.14M | $65.52M | $8.49M | $28.85M | $5.17M | 1.94× |
| 2017-06-30 | $127.88M | $48.30M | $30.28M | $78.99M | $18.62M | $4.80M | 2.65× |
| 2017-03-31 | $175.54M | $37.40M | $83.51M | $81.70M | $10.33M | $4.64M | 4.69× |
| 2016-12-31 | $53.10M | $38.73M | $13.41M | $37.72M | $1.96M | $5.34M | 1.37× |
| 2016-09-30 | (m) | $30.93M | $45.64M | $43.28M | (m) | $1.98M | (m) |
| 2016-06-30 | (m) | $27.89M | $61.94M | $12.70M | (m) | $3.31M | (m) |
| 2016-03-31 | (m) | $19.17M | $68.02M | $32.39M | (m) | $2.74M | (m) |
| 2015-12-31 | (m) | $19.73M | $75.18M | $55.99M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $16.45M | $152.99M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $16.59M | $171.53M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $11.63M | $55.56M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $13.62M | $72.67M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $11.27M | $86.21M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $10.79M | $105.01M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $7.38M | $57.48M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $6.99M | $72.29M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $5.50M | $22.60M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $9.59M | $34.85M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $7.60M | $45.72M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $4.15M | $53.51M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $4.24M | $60.05M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $3.12M | $12.44M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $3.36M | $13.44M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $3.69M | $17.97M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $2.54M | $21.02M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $3.20M | $21.33M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $1.08M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.56M | $2.11M | (m) | $110.00K | (m) | (m) |
| 2010-09-30 | (m) | (m) | $3.02M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $5.74M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $7.59M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $9.97M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |